3-乙炔基-4-甲基苯甲酸甲酯 | 1255099-13-8

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-乙炔基-4-甲基苯甲酸甲酯
• 英文名称: methyl 3-ethynyl-4-methylbenzoate
• CAS: 1255099-13-8
• 化学式: C₁₁H₁₀O₂
• 分子量: 174.199
• InChiKey: IJWDCLWLOGCXOQ-UHFFFAOYSA-N

物化性质

• 沸点：
  273.9±33.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C，干燥

反应信息

• 作为反应物：
  描述：

  3-乙炔基-4-甲基苯甲酸甲酯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 甲醇 、 水 为溶剂， 反应 22.0h， 生成 4-甲基-N-[4-[(4-甲基-1-哌嗪基)甲基]-3-(三氟甲基)苯基]-3-[2-(1H-吡唑并[3,4-b]吡啶-5-基)乙炔基]苯甲酰胺
  参考文献：
  名称：

  [EN] A PROCESS FOR PREPARING ALKYNYL-CONTAINING COMPOUND AND INTERMEDIATE THEREOF
  [FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ CONTENANT UN ALCYNYLE ET D'UN INTERMÉDIAIRE DE CELUI-CI

  摘要：

  本文披露了一种制备含炔基化合物及其中间体的方法（I）。特别地，本发明披露了一种制备如下式6所示的化合物的方法，以及包含如下式6的化合物的药物组合物，用于治疗癌症。

  公开号：

  WO2021164045A1
• 作为产物：
  描述：

  3-氨基-4-甲基苯甲酸甲酯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 硫酸 、 potassium carbonate 、 三乙胺 、 sodium nitrite 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 反应 3.0h， 生成 3-乙炔基-4-甲基苯甲酸甲酯
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2

  摘要：

  Discoidin-domain receptors 1 and 2 (DDR1 and DDR2) are new potential targets for anti-inflammatory-drug discovery. A series of heterocycloalkynylbenzimides were designed and optimized to coinhibit DDR1 and DDR2. One of the most promising compounds, Sn, tightly bound to DDR1 and DDR2 proteins with K-d values of 7.9 and 8.0 nM; potently inhibited the kinases with IC50 values of 9.4 and 20.4 nM, respectively; and was significantly less potent for a panel of 403 wild-type kinases at 1.0 mu M. DDR1- and DDR2-kinase inhibition by 5n was validated by Western-blotting analysis in primary human lung fibroblasts. The compound also dose-dependently inhibited lipopolysaccharide (LPS)-induced interleukin 6 (IL-6) release in vitro and exhibited promising in vivo anti-inflammatory effects in an LPS-induced-acute-lung-injury (ALI) mouse model. Compound 5n may serve as a lead compound for new anti-inflammatory drug discovery.

  DOI：

  10.1021/acs.jmedchem.8b01045

文献信息

• [EN] NEW COMPOUNDS AND METHODS<br/>[FR] NOUVEAUX COMPOSÉS ET PROCÉDÉS
  申请人：BENEVOLENTAI BIO LTD

  公开号：WO2020260871A1

  公开（公告）日：2020-12-30

  The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical compositions comprising the compounds of the invention, and to their use in the treatment or prevention of medical conditions in which inhibition of c-ABL is beneficial. (I)

  本发明涉及式(I)的化合物或其药用可接受的盐、溶剂化合物、水合物、互变异构体、光学异构体、N-氧化物和/或前药。本发明还涉及包括本发明化合物的药物组合物，以及它们在治疗或预防抑制c-ABL有益的医疗状况中的使用。
• Sonogashira Couplings Catalyzed by Fe Nanoparticles Containing ppm Levels of Reusable Pd, under Mild Aqueous Micellar Conditions
  作者：Sachin Handa、Bo Jin、Pranjal P. Bora、Ye Wang、Xiaohua Zhang、Fabrice Gallou、John Reilly、Bruce H. Lipshutz

  DOI：10.1021/acscatal.9b00007

  日期：2019.3.1

  Nanoparticles derived from FeCl3 containing the ligand XPhos and only 500 ppm Pd effect Sonogashira couplings in water between rt and 45 °C. The entire aqueous reaction medium can be easily recycled using an “in-flask” extraction. Several tandem processes in one pot are illustrated, including a sequence involving five steps (10 reactions) in good overall yield.

  含有配体XPhos和仅500 ppm Pd的FeCl 3衍生的纳米粒子在rt和45°C之间的水中会影响Sonogashira偶联。整个含水反应介质可以使用“烧瓶内”萃取法轻松回收。说明了一个罐中的几个串联过程，包括一个涉及五个步骤（10个反应）且总收率良好的序列。
• 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF
  申请人：Si Chuan University

  公开号：US20170305920A1

  公开（公告）日：2017-10-26

  The present invention relates to the field of chemical and medicine, more particularly, 3-ethynylpyrazolopyrimidine derivatives and their preparation methods and uses. The invention provides a 3-ethynylpyrazolopyrimidine derivative, and the structure is shown in formula I. The present invention also provides preparation methods and use of 3-ethynylpyrazolopyrimidine derivatives, comprising the compounds and derivatives, and their pharmaceutical compositions for the use of the treatment and prevention of tumors.

  本发明涉及化学和药物领域，更具体地涉及3-乙炔吡唑吡嘧啶衍生物及其制备方法和用途。该发明提供了一种3-乙炔吡唑吡嘧啶衍生物，其结构如公式I所示。本发明还提供了3-乙炔吡唑吡嘧啶衍生物的制备方法和用途，包括该化合物和衍生物，以及它们的药物组合物，用于治疗和预防肿瘤。
• Design, Synthesis, and <i>in vitro</i> Evaluation of P2X7 Antagonists
  作者：Dimitra T. Pournara、Anna Durner、Eftichia Kritsi、Alexios Papakostas、Panagiotis Zoumpoulakis、Annette Nicke、Maria Koufaki

  DOI：10.1002/cmdc.202000303

  日期：2020.12.15

  is a promising target for the treatment of various diseases due to its significant role in inflammation and immune cell signaling. This work describes the design, synthesis, and in vitro evaluation of a series of novel derivatives bearing diverse scaffolds as potent P2X7 antagonists. Our approach was based on structural modifications of reported (adamantan‐1‐yl)methylbenzamides able to inhibit the receptor

  由于 P2X7 受体在炎症和免疫细胞信号传导中的重要作用，它是治疗各种疾病的有希望的靶点。这项工作描述了一系列带有多种支架的新型衍生物作为有效的 P2X7 拮抗剂的设计、合成和体外评估。我们的方法基于已报道的（金刚烷-1-基）甲基苯甲酰胺的结构修饰，能够抑制受体激活。金刚烷部分和酰胺键被替换，并通过基于配体的药效团模型评估替换。通过双电极电压钳实验评估合成类似物的拮抗效力，使用非洲爪蟾表达人 P2X7 受体的卵母细胞。SAR 研究表明，用芳基-环己基部分取代金刚烷环是对抗 P2X7 阳离子通道激活的最有效拮抗剂，类似物 2-氯-N- [1-(3-(硝基氧基甲基)苯基)环己基)甲基]苯甲酰胺 ( 56 ) 表现出最佳效力，IC 50值为 0.39 μM。
• ppm Pd-catalyzed, Cu-free Sonogashira couplings in water using commercially available catalyst precursors
  作者：Bo Jin、Fabrice Gallou、John Reilly、Bruce H. Lipshutz

  DOI：10.1039/c8sc05618h

  日期：——

  A new catalyst that derives from commercially available precursors for copper-free, Pd-catalyzed Sonogashira reactions at the sustainable ppm level of precious metal palladium under mild aqueous micellar conditions has been developed. Both the palladium pre-catalyst and ligand are commercially available, bench stable, and highly cost-effective. The catalyst is applicable to both aryl- and heteroaryl-bromides

  一种新型催化剂源自市售前体，可在温和的水性胶束条件下以可持续的 ppm 级贵金属钯进行无铜、Pd 催化的 Sonogashira 反应。钯预催化剂和配体均可市售，工作台稳定且成本效益高。该催化剂适用于作为离析物的芳基溴和杂芳基溴。可以耐受多种官能团，并且水性反应介质可以循环利用。讨论了与活性药物成分（ponatinib）相关的关键中间体的应用。